June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
In vitro characterization of anti-angiogenic effects of DS-7080a, a novel anti-human ROBO4 monoclonal antibody
Author Affiliations & Notes
  • Yoshitaka Isumi
    Biologics & Immuno-Oncology Laboratories, Daiichi Sankyo Co., Ltd., Tokyo, Japan
  • Tatsuya Inoue
    Pain & Neuroscience Laboratories, Daiichi Sankyo Co., Ltd., Tokyo, Japan
  • Shinko Hayashi
    Biologics & Immuno-Oncology Laboratories, Daiichi Sankyo Co., Ltd., Tokyo, Japan
  • Chigusa Yoshimura
    Modality Research Laboratories, Daiichi Sankyo Co., Ltd., Tokyo, Japan
  • Jun Hasegawa
    Modality Research Laboratories, Daiichi Sankyo Co., Ltd., Tokyo, Japan
  • Toshiyuki Sato
    Pain & Neuroscience Laboratories, Daiichi Sankyo Co., Ltd., Tokyo, Japan
  • Toshinori Agatsuma
    Biologics & Immuno-Oncology Laboratories, Daiichi Sankyo Co., Ltd., Tokyo, Japan
  • Footnotes
    Commercial Relationships   Yoshitaka Isumi, Daiichi Sankyo Co., Ltd. (E); Tatsuya Inoue, Daiichi Sankyo Co. Ltd (E); Shinko Hayashi, Daiichi Sankyo Co., Ltd. (E); Chigusa Yoshimura, Daiichi Sankyo Co., Ltd. (E); Jun Hasegawa, Daiichi Sankyo Co., Ltd. (E); Toshiyuki Sato, Daiichi Sankyo Co., Ltd. (E); Toshinori Agatsuma, Daiichi Sankyo Co., Ltd. (E)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 1962. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Yoshitaka Isumi, Tatsuya Inoue, Shinko Hayashi, Chigusa Yoshimura, Jun Hasegawa, Toshiyuki Sato, Toshinori Agatsuma; In vitro characterization of anti-angiogenic effects of DS-7080a, a novel anti-human ROBO4 monoclonal antibody. Invest. Ophthalmol. Vis. Sci. 2017;58(8):1962.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To characterize in vitro the anti-angiogenic effects of DS-7080a, an anti-human roundabout 4 (hROBO4) monoclonal antibody (mAb), possibly indicated for the treatment of angiogenesis-related eye disease such as wet AMD.

Methods : DS-7080a antigen-binding activity was measured by a cell enzyme-linked immunosorbent assay. In vitro anti-angiogenic effects contrasting the action of various angiogenic factors were evaluated by a HUVEC migration assay. Primary human retinal pigmented epithelial cells were cultured using Transwell for about one month before collecting conditioned media.

Results : DS-7080a bound to hROBO4 with a Kd of 0.065 nM, while it did not bind to any other ROBO proteins. HUVEC migration was induced by multiple angiogenic factors such as vascular endothelial growth factor, basic fibroblast growth factor, and hepatocyte growth factor and was inhibited by 37.3, 48.5 and 26.6%, respectively, by 2 μg/mL of DS-7080a. Conditioned media from primary human retinal pigmented epithelial cells was found to induce HUVEC migration, which was inhibited by either DS-7080a (by 77.1% at 1.458 μg/mL) or ranibizumab (by 83.1% at 0.484 μg/mL) alone or in combinaton (125.9%).

Conclusions : DS-7080a shows specific binding to hROBO4 with potent inhibitory effects on HUVEC migration. It may be a therapeutic option for angiogenesis-related diseases where multiple angiogenic factors are involved such as wet AMD.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×